BreakBio Appoints Greg Lizée as Chief Scientific Officer
Position
Chief Scientific Officer
Company
BreakBio
Description
BreakBio has announced the appointment of Greg Lizée, Ph.D., as their new Chief Scientific Officer. Dr. Lizée joins from the University of Texas MD Anderson Cancer Center and brings extensive expertise in tumor immunology and personalized cancer therapies.
Other recent leadership changes in Therapeutics and Biotechnology
Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.
- Liquidia Corporation Appoints Russell Schundler as Chief Strategy Officer and General Counsel (November 19, 2026)
- Dr. Eric Hughes Resigns from Teva Pharmaceutical (November 19, 2026)
- GOA Therapeutics Appoints Scott Howell as Chief Commercial Officer (November 18, 2026)
- CytoDyn Inc. Appoints Dr. Lauren Wilcoxen as Chief Operating Officer (November 18, 2026)
- Nomad Power Solutions Appoints Michael Hilmer as Interim Chief Executive Officer (November 16, 2026)
- Nasus Pharma Appoints Nir Sassi as Chief Financial Officer (November 16, 2026)
Who to call at BreakBio, and when
A new leader at BreakBio brings new priorities and often new vendors. The first weeks are when they listen.
- An alert the day BreakBio raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at BreakBio, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at BreakBio. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment BreakBio changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
BreakBio changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.